SCHEMBL3323592

SCHEMBL3323592

CCCOC(=O)C1=C(C)NC2=C(C(=O)CC(c3ccccc3)C2)C1c1ccc(Cl)cc1Cl

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 10/20 0.48
HPGD P15428 6/20 0.48
HSD17B10 Q99714 5/20 0.48
CASP1 P29466 3/20 0.48
CASP7 P55210 3/20 0.48
BAP1 Q92560 1/20 0.48
KDM4E B2RXH2 12/20 0.48
POLB P06746 3/20 0.48
LMNA P02545 2/20 0.48
AGTR1 P30556 1/20 0.48
MAPK1 P28482 2/20 0.47
USP2 O75604 1/20 0.47
RAB9A P51151 1/20 0.47
GAA P10253 3/20 0.47
HTT P42858 3/20 0.47
NPSR1 Q6W5P4 3/20 0.47
ALOX12 P18054 1/20 0.47
L3MBTL1 Q9Y468 1/20 0.47
TP53 P04637 2/20 0.46
ALOX15 P16050 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3329937 0.89 ALDH1A1 (0.51) ALDH1A1HPGDHSD17B10CASP1CASP7
SCHEMBL3323801 0.86 ALDH1A1 (0.57) ALDH1A1HPGDHSD17B10CASP1CASP7
SCHEMBL5332348 0.84 KDM4E (0.51) ALDH1A1HPGDHSD17B10CASP1CASP7
SCHEMBL3329613 0.83 ALDH1A1 (0.51) ALDH1A1HPGDHSD17B10CASP1CASP7
SCHEMBL3324836 0.83 ALDH1A1 (0.61) ALDH1A1HPGDHSD17B10CASP1CASP7
SCHEMBL3323422 0.83 KDM4E (0.61) ALDH1A1HPGDHSD17B10CASP1CASP7
SCHEMBL3324425 0.82 ALDH1A1 (0.55) ALDH1A1HPGDHSD17B10CASP1CASP7
SCHEMBL3323109 0.82 ALDH1A1 (0.69) ALDH1A1HPGDHSD17B10CASP1CASP7
SCHEMBL3325469 0.81 KDM4E (0.50) ALDH1A1HPGDHSD17B10CASP1CASP7
SCHEMBL3324895 0.81 KDM4E (0.68) ALDH1A1HPGDHSD17B10CASP1CASP7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100119599-A1 POLYHYDROQUINOLINE COMPOUNDS AND DIHYDROPYRIDINE COMPOUNDS FOR INHIBITING BETA-AMYLOID PRODUCTION ARCHER PHARMACEUTICALS, INC. (US) 2010-05-13 US disclosed
US-20100119599-A1 POLYHYDROQUINOLINE COMPOUNDS AND DIHYDROPYRIDINE COMPOUNDS FOR INHIBITING BETA-AMYLOID PRODUCTION ARCHER PHARMACEUTICALS, INC. (US) 2010-05-13 US disclosed
US-20100119599-A1 POLYHYDROQUINOLINE COMPOUNDS AND DIHYDROPYRIDINE COMPOUNDS FOR INHIBITING BETA-AMYLOID PRODUCTION ARCHER PHARMACEUTICALS, INC. (US) 2010-05-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100119599-A1 POLYHYDROQUINOLINE COMPOUNDS AND DIHYDROPYRIDINE COMPOUNDS FOR INHIBITING BETA-AMYLOID PRODUCTION APP, MAPT, PSEN1 ALDH1A1 2615/4885HPGD 265/4885HSD17B10 1530/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.